Background The relative absence of coronary atherosclerosis in premenopausal women has been established. Estrogen is presumed to play a role in the protection of coronary arteries from atherosclerosis, and part of this protective effect appears to be mediated by amelioration of serum lipid profiles. However, all of the atheroprotective effect of estrogen is not explained by alteration of serum lipids. In this study, we attempt to identify evidence of estrogen receptors in coronary artery specimens of female patients and in human vascular
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Methods and Results Postmortem coronary artery specimens were obtained from premenopausal (n=18) and postmenopausal (n=22) women who died with significant coronary artery disease (n= 19) and from noncardiac causes with normal coronary arteries (n=21). Sections were examined for evidence of estrogen receptor expression using a monoclonal antibody stain. Radioligand binding assays for estrogen receptors were performed on human vascular smooth muscle cells in culture, and gel retardation assays were performed to confirm the presence of functional estrogen receptors. Estrogen receptor expression was identified by immunostaining in a total of 21 coronary arteries, with the majority of normal arteries (15 positive of 21 total, P=.0117) demonstrating evidence of estrogen receptor expression. Conversely, a minority (6 of 19, P=NS) of atherosclerotic arteries were positive for estrogen receptor expression. Furthermore, the relation between estrogen receptor expression and absence of coronary atherosclerosis was most evident in premenopausal subjects, with 10 of 12 normal arteries in this group demonstrating evidence of estrogen receptors, whereas only 1 of 6 atherosclerotic coronary arteries was positive (P=.0062). Radioligand T he relative protection from coronary atherosclerosis conferred upon premenopausal women is well established. Heberden commented on the sex difference in the incidence of angina pectoris in 1803.1 Others have documented the lower incidence of coronary atherosclerosis in premenopausal women in epidemiological and autopsy studies.2-6 The increased incidence of atherosclerosis in women who undergo premature menopause also has been well described.7-12 Finally, there is increasing evidence that treatment with replacement estrogen after menopause will reduce cardiovascular mortality. 13-'5 Animal studies have provided further evidence of the effects of estrogen on the vascular system. Estrogen treatment prevented collagen and elastin accumulation in the aortic wall in normotensive rats'6 and thickening of the aorta in hypertensive rats17 and similarly suppressed atherosclerosis in primate coronary arteries. 18 Alternatively, progesterone administered alone resulted in an increase in fatty streak formation in castrated baboons, whereas animals receiving estradiol and progesterone together had the fewest lesions.19 Thus, in an intact animal preparation, there have been multiple studies clearly suggesting an effect of sex steroids on vascular biology and specifically suggesting an antiproliferative effect of estrogen. These studies lend experimental support to the hypothesis, brought forward by epidemiological studies, that female sex hormones are protective against coronary atherosclerosis. What these studies do not address, however, is the mechanism whereby the presence of estrogen is translated into an effect on the biology of the arterial wall.
Endogenous 
Methods

Coronary Artery Specimens
The autopsy records of St Elizabeth's Hospital were reviewed to identify patients who had undergone cardiac postmortem examination and who met criteria for one of the following four categories: (1) premenopausal women without coronary disease, (2) premenopausal women with severe coronary atherosclerosis, (3) postmenopausal women with normal coronary arteries, or (4) postmenopausal women with severe coronary atherosclerosis.
For the purposes of this study, severe atherosclerosis was defined as a luminal cross-sectional area narrowing of >75% measured histologically. We specifically attempted to identify the maximum number of premenopausal women with atherosclerosis, since testing our hypothesis would rely to a large extent on examination of specimens from this group. It was anticipated that coronary artery specimens from this group would be the least numerous and that the remaining categories would then be matched in size.
Estrogen Receptor Immunohistochemical Staining
Although assays of fresh-frozen tissue remain the standard for estrogen receptor analysis in breast carcinoma, prior studies have demonstrated specific identification of estrogen receptor protein by monoclonal antibodies applied to formalin-fixed, paraffin-imbedded tissue. 33, 34 In this investigation, we applied a method developed by Hiort et al,34 which was verified previously against the results of the standard biochemical assay for estrogen receptors. This technique uses a commercially available antibody preparation (Abbott Laboratories). A total of 12 sections from each specimen were examined immunohistochemically.
Slides were deparaffinized in xylene and ethanol and rinsed in phosphate-buffered saline (PBS). Sections then were transferred to a solution of Ficin (Sigma Chemicals) for 15 minutes. After rinsing in tap water, the slides then were immersed in PBS and transferred to incubation dishes. Sections were covered with two or three drops of DNase solution (5 mg DNase [Sigma Chemicals] per milliliter of 0.05 M Tris, pH 7.4, with 1.2 MgSO4). After 15 minutes, sections were rinsed in PBS, and the blocking agent (normal goat serum) from the manufacturer's kit was added for 15 minutes. After draining the blocking agent, the primary antibody was applied, and the slides were incubated at 4°C overnight. Sections then were rinsed in PBS, and bridging antibody was applied for 30 minutes at room temperature. Endogenous peroxidase activity then was blocked with the application of solution consisting of 80 mL methyl alcohol plus 20 mL 3%1 H202. After 30 minutes, slides were rinsed with tap water, after which PBS and a solution of peroxidase-antiperoxidase were added for 1 hour. The chromogen solution consisted of diaminobenzidine (DAB), cobalt chloride (CoCI), and hydrogen peroxide Estrogen Receptor Radioligand Binding Assay
Estrogen receptor assay was performed using a radioligand binding assay, which was developed for use in evaluating the estrogen receptor status of breast carcinoma and has been adapted for use in cell culture. Human vascular smooth muscle cells growing in 24-well plates were exposed to (2,4,6,7-3H)estradiol (New England Nuclear) in concentrations from 1 to 40 nmol/L, alone or in the presence of 200-fold excess unlabeled 17-,3-estradiol. The cells were allowed to incubate at 37°C for 30 minutes. The cell culture plates then were placed on ice, the medium was aspirated, and cells were washed five times in ice-cold calcium and magnesium-free PBS. The bound, labeled estradiol was then solubilized with 70% EtOH, and total radioactivity was determined by liquid scintillation counting. All assays were performed in duplicate.
Calculation of receptor number was performed according to the method of Scatchard.36 Specific binding of radiolabeled ligand was determined by subtraction of bound radioactivity in the wells in which excess unlabeled steroid was present from the bound radioactivity in the wells incubated without unlabeled hormone. Receptor numbers were calculated per 106 cells.
Gel Shift Assay
Gel shift assays are widely used in the study of DNA binding proteins, including receptors. The assay is based on the fact that complexes of DNA and protein will migrate more slowly through a polyacrylamide gel than uncomplexed DNA. We used the gel shift assay to identify the presence of estrogen receptor protein in the extract from hVSMC. In the presence of estrogen, the estrogen receptor should form a complex with the estrogen response element. By labeling the response element with 32p, the complexes can be identified by their altered electrophoretic mobility.
Whole-Cell Extract Preparation
Confluent 100-mm plates of cultured hVSMC were incubated in 10% charcoal-stripped FBS in phenol red-free M199 for 48 hours, after which some of the cells were exposed to estradiol (10`7 mol/L) for 1 hour. Cells were then lysed by freezing at -80°C in 0.1 mL of buffer containing 20 mmol/L Tris-HCl, 2 mmol/L DTT, 0.4 mol/L KCl, and 20% glycerol. Cells were thawed over ice and centrifuged for 20 minutes at 4°C. The supernatant was used as the crude whole-cell extract.
Estrogen Response Element
Previously published sequences for the estrogen response element (ERE)37 were synthesized commercially and dimerized at room temperature to form a double-stranded oligonucleotide probe.
S'-End Labeling
The 37-bp probe containing the ERE was end-labeled with 32p in a reaction catalyzed by T4 polynucleotide kinase. according to the manufacturer's guidelines (Promega).
Gel Shift Assay
Whole-cell extracts from hVSMC that had been incubated in the presence or absence of estradiol were incubated with 
Results
Subjects
The age range of the study cohort is shown in antibody to smooth muscle a-actin stain is also shown and demonstrates the presence of smooth muscle cells both in the intima and the media. The location of the a-actin-positive cells in the media corresponds to the location of the estrogen receptor-positive cells seen above.
Estrogen receptor expression in the coronary arteries of all subjects studied is shown in Table 2 . Of the 21 normal arteries studied, 15 (71.4%) of these showed evidence of estrogen receptor expression; in contrast, among 19 atherosclerotic arteries, 13 (68.4%) showed no evidence of estrogen receptor expression when assayed immunohistochemically. Contingency table analysis revealed that differences between these groups were statistically significant (P=.0117).
The association between the presence of estrogen receptor expression and absence of coronary atherosclerosis was highly significant when the results of staining of arteries of premenopausal women were analyzed separately. In 12 normal arteries, estrogen receptor expression was shown immunohistochemically in 10 (83.3%), whereas in 5 of 6 atherosclerotic arteries, no evidence of estrogen receptor expression was observed. The differences between these groups were highly statistically significant, with P=.0062 (Table 2) . When the results of the immunohistochemical staining for estrogen receptor expression in the coronary arteries of postmenopausal subjects were analyzed separately, the impact of estrogen receptor expression was no longer evident (Table 2 ). In nine normal coronary arteries of postmenopausal female patients, estrogen receptor expression was observed in five (55.6%) and was absent in four (44.4%). Among the atherosclerotic There were several confounding issues raised by the initial immunohistochemistry. Although the evidence of positive staining of arterial tissue was consistently observed, the staining pattern was not always typical of that seen in other tissues studied by this technique, particularly breast cancer. This may be due in part to the well-known difficulty in detecting the estrogen receptor immunohistochemically in specimens stored in formalin and may be compounded by the fact that the majority of the specimens used in this study had been stored for many years. The pattern of staining seen in some specimens raised questions as to the precise location of estrogen receptors in coronary arteries.
In addition, this immunohistochemical method is qualitative, making a precise quantification of receptor expression impossible. The positive control tissue used in all cases was a sample of breast carcinoma, which had been independently shown to be expressing estrogen receptors at high levels. This raised the possibility that tissues defined as "estrogen receptor negative" by this technique may have been expressing estrogen receptors at some level lower than that of the control tissue and therefore were arbitrarily defined as negative. Furthermore, the possibility of a threshold level of estrogen receptor expression necessary for atheroprotection could legitimately be raised by these findings.
To action of estrogen on arterial biology possible. While the mechanism(s) of a direct genomic effect of estrogen remain to be elucidated, this investigation provides evidence that such an effect of estrogen on vascular smooth muscle cell biology is possible and may account for the "non-lipid-mediated" atheroprotective effect of estrogen.
